Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 엄지은 | - |
dc.date.accessioned | 2016-06-20T01:53:41Z | - |
dc.date.available | 2016-06-20T01:53:41Z | - |
dc.date.issued | 2012-01 | - |
dc.identifier.citation | LUNG CANCER, v. 75, Page. 82-88 | en_US |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S0169500211003199 | - |
dc.description.abstract | Purpose Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (NSCLC). Patients and methods Patients with locally advanced, metastatic stage IIIB/IV NSCLC who failed first-line chemotherapy and had either EGFR mutation or at least two out of three clinical factors associated with higher incidence of EGFR mutations (female, adenocarcinoma histology, and never-smoker) were eligible. Results A total of 96 (48 per arm) patients were randomly assigned to gefitinib- or erlotinib-arm, respectively. Baseline characteristics were well-balanced between the two arms. The response rates (RR) were 47.9% in the gefitinib arm and 39.6% in the erlotinib arm. Median PFS was 4.9 months (95% CI, 1.3–8.5) in the gefitinib arm and 3.1 months (95% CI, 0.0–6.4) in the erlotinib arm. The most common grade 3/4 toxicity was skin rash. Exploratory analyses showed that there was no significant difference in RR and PFS in the gefitinib arm compared to the erlotinib arm (RR (%) 47.9 vs. 39.6, p = 0.269; median survival (months) 4.9 vs. 3.1, p = 0.336). There was no significant difference in QOL between the two arms. Conclusion Both gefitinib and erlotinib showed effective activity and tolerable toxicity profiles as second-line treatment for the selected population of NSCLC. We may consider conducting a phase III trial to directly compare the efficacy and toxicity between gefitinib and erlotinib in an enriched patient population. | - |
dc.description.sponsorship | This study was supported by IN-SUMG Foundation for Medical Research (CA98711). | - |
dc.publisher | ELSEVIER IRELAND LTD | en_US |
dc.subject | Gefitinib | - |
dc.subject | Erlotinib | - |
dc.subject | Non-small cell lung cancer | - |
dc.title | Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy | en_US |
dc.type | Article | en_US |
dc.relation.volume | 75 | - |
dc.identifier.doi | 10.1016/j.lungcan.2011.05.022 | - |
dc.relation.page | 82-88 | - |
dc.relation.journal | LUNG CANCER | - |
dc.contributor.googleauthor | Kim, Seung Tae | - |
dc.contributor.googleauthor | Uhm, Ji Eun | - |
dc.contributor.googleauthor | Lee, Jeeyun | - |
dc.contributor.googleauthor | Sun, Jong-mu | - |
dc.contributor.googleauthor | Sohn, Insuk | - |
dc.contributor.googleauthor | Kim, Seon Woo | - |
dc.contributor.googleauthor | Jung, Sin-Ho | - |
dc.contributor.googleauthor | Park, Yeon Hee | - |
dc.contributor.googleauthor | Ahn, Jin Seok | - |
dc.contributor.googleauthor | Park, Keunchil | - |
dc.relation.code | 2012206399 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.